Vaxart (NASDAQ: VXRT) insider files Rule 144 to sell 40,000 shares

Rhea-AI Filing Summary

Vaxart insider Michael Finney has filed a notice to sell up to 40,000 shares of VXRT common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $14,400.00 listed in the filing. The document also notes that 240,069,844 shares of the issuer’s stock are outstanding.

The 40,000 shares were originally acquired on 02/13/2018 in a private cash transaction from the issuer or an affiliate. In addition, the filing lists recent sales over the past three months, including 51,179 VXRT shares sold on 12/01/2025 for gross proceeds of $18,927.93. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about Vaxart.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	40000	14400.00	240069844	12/08/2025	OTCLNK

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/13/2018	Private Acquisition from Issuer/Affiliate	Issuer			40000	02/13/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael Finney 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080	VXRT	12/03/2025	15112	5430.86
Michael Finney 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080	VXRT	12/02/2025	24032	8887.85
Michael Finney 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080	VXRT	12/02/2025	3000	1106.30
Michael Finney 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080	VXRT	12/01/2025	2500	923.88
Michael Finney 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080	VXRT	12/01/2025	51179	18927.93

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the VXRT Form 144 filing by Michael Finney disclose?

The filing shows that Michael Finney plans to sell up to 40,000 shares of Vaxart (VXRT) common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $14,400.00 stated in the document.

How many Vaxart (VXRT) shares are outstanding according to this notice?

The notice lists 240,069,844 shares of Vaxart common stock as outstanding.

When and how did the seller acquire the VXRT shares covered by this Form 144?

The 40,000 VXRT shares were acquired on 02/13/2018 in a private acquisition from the issuer or an affiliate, and the filing states that the purchase was paid in cash on that date.

Which broker is handling the planned VXRT share sale under Rule 144?

The planned sale of 40,000 VXRT shares is listed as being handled by Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

What recent VXRT stock sales by the same seller are disclosed?

The filing lists several VXRT sales over the past three months by Michael Finney, including a transaction on 12/01/2025 where 51,179 shares were sold for gross proceeds of $18,927.93, along with additional smaller trades on 12/01/2025, 12/02/2025, and 12/03/2025.

Does the VXRT Form 144 include a representation about undisclosed information?

Yes. By signing the notice, the person for whose account the securities are sold represents that they do not know any material adverse information about Vaxart’s current or prospective operations that has not been publicly disclosed.